American Renal Associates Holdings Inc (NYSE:ARA) – Research analysts at Svb Leerink cut their FY2019 earnings estimates for American Renal Associates in a note issued to investors on Monday, April 1st, Zacks Investment Research reports. Svb Leerink analyst A. Gupte now forecasts that the company will post earnings of $0.34 per share for the year, down from their prior estimate of $0.56. Svb Leerink currently has a “Market Perform” rating on the stock. Svb Leerink also issued estimates for American Renal Associates’ FY2020 earnings at $0.39 EPS.
A number of other equities analysts have also recently commented on the company. Leerink Swann cut American Renal Associates to a “market perform” rating in a report on Monday, March 11th. ValuEngine cut American Renal Associates from a “hold” rating to a “sell” rating in a report on Monday, January 7th. SunTrust Banks reiterated a “buy” rating and issued a $16.00 target price on shares of American Renal Associates in a report on Wednesday, January 9th. Deutsche Bank started coverage on American Renal Associates in a report on Thursday, January 3rd. They issued a “hold” rating and a $12.00 target price for the company. Finally, Barclays set a $9.00 target price on American Renal Associates and gave the stock a “hold” rating in a report on Thursday, March 28th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $15.92.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Squarepoint Ops LLC purchased a new position in American Renal Associates during the 4th quarter valued at $125,000. Rhumbline Advisers boosted its holdings in American Renal Associates by 47.5% during the 4th quarter. Rhumbline Advisers now owns 17,225 shares of the company’s stock valued at $198,000 after acquiring an additional 5,549 shares during the period. MetLife Investment Advisors LLC purchased a new position in American Renal Associates during the 3rd quarter valued at $230,000. Strs Ohio boosted its holdings in American Renal Associates by 88.7% during the 1st quarter. Strs Ohio now owns 60,000 shares of the company’s stock valued at $368,000 after acquiring an additional 28,200 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in American Renal Associates by 21.2% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 33,900 shares of the company’s stock valued at $391,000 after acquiring an additional 5,925 shares during the period. Institutional investors own 95.31% of the company’s stock.
American Renal Associates Company Profile
American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.
Recommended Story: How to Use a Moving Average for Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.